Screening of Postpartum Depression in Egyptian Women

February 11, 2025 updated by: Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy, Al-Azhar University

Assessment of the Edinburgh Postnatal Depression Scale as Screening Tool for Postpartum Depression Among Women Delivering at Egyptian Tertiary Care System University Hospital: Prevalence and Risk Factors Analysis

The goal of this cross-sectional study is to assess the Edinburgh Postnatal Depression Scale as screening tool for Postpartum Depression among women delivering at Egyptian tertiary health care system, University Hospital, regarding Prevalence and risk factors.

participants of this study with fill the Edinburgh Postnatal Depression Scale and their socio-demographic, obstetric and psychological data will be collected and analysed.

prevalence of postpartum depression in Egyptian women will be assessed as well as the associated risk factors

Study Overview

Status

Completed

Conditions

Postpartum Depression

Intervention / Treatment

Other: Edinburgh Postnatal Depression Scale

Study Type

Observational

Enrollment (Actual)

2000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Egypt
- Cairo.
  - Cairo, Cairo., Egypt
    - Faculty od Medicine, Department of Obstetrics and Gynecology.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

2000 patients who underwent either vaginal birth or cesarean section at El-Hussien University Hospital and agreed for followup and participation in this study.

Description

Inclusion Criteria:

All patients who underwent vaginal/cesarean delivery and reported for follow and willing to participate in the study.

Exclusion Criteria:

Patients who were unwilling to participate in the study.
Patients who are having difficulties comprehending the questionnaire of the study.
Women who were on psychiatric medication during pregnancy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number screening positive for possible postpartum depression by Arabic EPDS Time Frame: 2 weeks postpartum	Number of participants screening positive for possible postpartum depression, defined as a score of 13 or higher on the validated Arabic version of the Edinburgh Postnatal Depression Scale (EPDS) Participants with a positive screen (EPDS score ≥13) will be referred for psychiatric consultation for diagnostic confirmation and treatment of postpartum depression	2 weeks postpartum

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Sociodemographic, clinical, and psychosocial predictors of postpartum depression risk Time Frame: At 2 weeks postpartum	Identification of sociodemographic, clinical, and psychosocial risk factors associated with screening positive for possible postpartum depression, as determined by bivariate and multivariate regression analyses of factors correlated with an Arabic EPDS score ≥13. Sociodemographic factors will include maternal age, education level, occupation, socioeconomic status, etc. Clinical factors will include obstetric history, delivery method, neonatal health status, etc. Psychosocial factors will include social support, stress levels, family dynamics, etc.	At 2 weeks postpartum

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Al-Azhar University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2023

Primary Completion (Actual)

August 30, 2024

Study Completion (Actual)

September 1, 2024

Study Registration Dates

First Submitted

August 3, 2023

First Submitted That Met QC Criteria

August 9, 2023

First Posted (Actual)

August 18, 2023

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 11, 2025

Last Verified

February 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

520235

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Studies a U.S. FDA-regulated device product

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.